Showing 2941-2950 of 3069 results for "".
- Zwivel and CareCredit Team Uphttps://practicaldermatology.com/news/zwivel-and-carecredit-team-up/2458836/CareCredit, a provider of patient financing, and Zwivel, an online cosmetic consultation platform that enables cosmetic patients and doctors to interact prior to an in-office consultation, signed a marketing agreement enabling consumers to apply for a CareCredit health, wellness, and beauty credi
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Radiesse from Merz Aesthetics Approved for Handshttps://practicaldermatology.com/news/radiesse-from-merz-aesthetics-approved-for-hands/2458934/Radiesse® from Merz Aesthetics received FDA approval for hand augmentation to correct volume loss in the dorsum of the hands. Radiesse® provides an immediate volumizing effect and can help to reduce the prom
- Survey Reveals Attitudes About Lip Healthhttps://practicaldermatology.com/news/survey-reveals-attitudes-about-lip-health/2458937/The majority of Americans suffer from dry and chapped lips, and 1 in 4 say that when their lips are chapped and flaky they don’t look attractive. Furthermore, close to 1 in 5 say their self-confidence goes down when their lips are chapped and flaky and, some even
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- Cipher Pharmaceuticals Acquires Innocutishttps://practicaldermatology.com/news/cipher-pharmaceuticals-acquires-innocutis/2458969/Cipher Pharmaceuticals Inc. has acquired Innocutis Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash. (All financial references are in U.S. dollars unless otherwise noted.) "This acquisition marks our commercial entry to the U.S. market an
- Aclaris Therapeutics' A-101 Achieves Positive Results in Clinical Trial for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-a-101-achieves-positive-results-in-clinical-trial-for-seborrheic-keratosis/2458989/Aclaris Therapeutics, Inc.’s lead drug candidate A-10 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face in its third Phase II clinical trial. The double-blind, vehicle-controlled Phase 2 clinical trial was designed t
- Practical Dermatology® and NewDerm MD Announce Social Media Contesthttps://practicaldermatology.com/news/practical-dermatology-and-newderm-md-announce-social-media-contest/2458994/Follow NewDermMD on Twitter (@NewDermMD) and download the NewDermMD app and complete a brief survey between March 18 to April 17 for your chance to win a FujiFilm XQ2 Digital Camera with wi-fi for your practice. Dedicated to future lead
- Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002https://practicaldermatology.com/news/revance-launches-phase-2-belmont-study/2459035/Specialty biopharmaceutical company Revance Therapeutics, Inc. has initiated the BELMONT trial, a Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and